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Available online 27 April 2016The objective of this study is to evaluate the association between tumor grade and response to chemotherapy in
patients with endometrioid endometrial adenocarcinoma.
Patients with advanced or recurrent endometrioid endometrial adenocarcinoma of known tumor grade who
received at least 3 cycles of chemotherapywere retrospectively identiﬁed at three institutions. RECIST 1.1 criteria
were used to assess response to neoadjuvant, postoperative or salvage chemotherapy. Chi-square testing was
used to evaluate the association between tumor grade and chemotherapy response.
Ninety-one patients met inclusion criteria: 13 with grade 1, 29 with grade 2 and 49with grade 3 tumors. Eighty-
four percent of patients received chemotherapy for recurrence, 12% for postoperative residual disease, and 4% in
the neoadjuvant setting. Themajority (85%) received carboplatin and paclitaxel. Forty-six percent (6/13) of grade
1, 72% (21/29) of grade 2 and 43% (21/49) of grade 3 tumors achieved an objective response. Grade 2 tumors
were more likely to respond to chemotherapy compared to grade 3 tumors (72% vs. 43%, p = 0.02; Table 2),
and speciﬁcally more likely to respond to carboplatin/paclitaxel (72% vs. 41%, p = 0.016). Median progression-
free survival for patients receiving chemotherapy for recurrence or progressionwas 9months for grade 1, 8months
for grade 2, and 5months for grade 3 tumors. Similar results between grade and treatment responsewere apparent
in the subset of 37 patients with a recently re-assigned tumor grade (G2 88% vs. G3 44%, p = 0.032).
In this series of endometrioid endometrial cancers, grade 2 tumors had the best measurable response to
chemotherapy.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Resistance1. Introduction
Endometrial cancer (EC) is the most common gynecologic malignan-
cy, frequently presenting in early stages. For women with localized dis-
ease at diagnosis, 5-year survival rates exceed 90% (Siegel et al., 2014).
For those with distant disease at diagnosis, 5-year survival is below 20%
(Siegel et al., 2014).While early disease is often cured byprimary surgery,
adjuvant therapy is often administered for more advanced cases
(Network NCC, 2014). According to the most recent National Compre-
hensive Cancer Network (NCCN) guidelines for EC, chemotherapy with
or without the addition of radiation is considered to be the cornerstone
of treatment for patients with surgically staged advanced disease. Certain
risk features in women with early stage disease—advanced age,7710., United States.
idson).
. This is an open access article underlymphovascular space invasion, large tumor size, lower uterine segment
or surface cervical glandular involvement—may also receive adjuvant
chemotherapy (Network NCC, 2014).
Chemoresistance remains an important factor in themanagement of
EC. In GOG-177, a trial evaluating doxorubicin and cisplatin +/− pacli-
taxel in women with advanced or recurrent endometrial cancer, 25% of
regimens were discontinued due to progressive disease (Fleming et al.,
2004). Response durations in EC tend to be shorter than those for ovar-
ian cancer (McMeekin et al., 2007). Over half of patients don't respond
to NCCN-recommended regimens at all (Network NCC, 2014;
McMeekin et al., 2007) andmay suffer from treatment-related toxicities
without beneﬁt. Ideally, chemotherapy would be used only in those
likely to respond, while the predicted non-responders would receive
other treatmentmodalities. With some data suggesting that genetic ag-
gressiveness generally trendswith grade, the objective of our studywas
to ascertain the association of tumor grade with chemotherapy re-
sponse in patients with EEC.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patient characteristics by tumor grade on most recent biopsy.
Grade 1
n = 13(%)
Grade 2
n = 29(%)
Grade 3
n = 49(%)
Total
n = 91
Age at diagnosis, mean 62.4 63.4 62.6 63.0
Race/ethnicity
Caucasian/non-Hispanic 10 (77) 24 (83) 32 (65) 66
Caucasian/Hispanic 0 0 2 (4) 2
African-American 1 (8) 4 (14) 14 (29) 19
Other 2 (15) 1 (3) 1 (2) 4
BMI at diagnosis, mean 29.6 33.9 33.5 33.1
Chemotherapy setting
Neoadjuvant 2 (15) 0 3 (6) 5
Post-operative 1 (7) 3 (10) 6 (12) 10
Recurrence 10 (77) 26 (90) 40 (82) 76
Stage at presentation
I 5 (38) 18 (62) 21 (43) 44
II 0 2 (7) 4 (8) 6
III 2 (15) 4 (14) 13 (27) 19
IV 6 (46) 5 (17) 11 (22) 22
Lymph nodes removed,
mean (range)
Pelvic 4 (0–12) 14 (0–45) 13 (0–53) 12
Para-aortic 2 (0–7) 3 (0–17) 5 (0–29) 4
Received prior chemotherapy 5 (38) 4 (14) 9 (18) 18 (20)
Target in prior irradiated ﬁeld (n) 2 8 9 19
Chemotherapy regimen
Carboplatin/paclitaxel 9 (68) 25 (87) 34 (69) 68 (75)
Cisplatin/doxorubicin/paclitaxel 1 (8) 1 (3) 2 (4) 4 (4)
Cisplatin/pegylated liposomal
doxorubicin
1 (8) 1 (3) 1 (2) 3 (3)
Gemcitabine/docetaxel 1 (8) 0 0 1 (1)
Other 1 (8) 2 (7) 13 (25) 16 (17)
BMI: Body mass index.
Table 2
Response to chemotherapy based on most recent tumor grade.
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We conducted a multi-institutional IRB-approved retrospective
study of EC at Duke University, the University of North Carolina-
Chapel Hill (UNC) or the Medical University of South Carolina (MUSC).
Inclusion criteria were advanced or recurrent EEC, documented tumor
grade, treatment with chemotherapy between 1994 and 2013, and
measurable disease using RECIST 1.1 criteria (RECIST, 2014). Patients
must have received a minimum of 3 cycles of chemotherapy and have
pre-and post-chemotherapy imaging available for review. Patients
with recurrent disease were included for their response to salvage
chemotherapy for measurable disease. Exclusion criteria were non-
endometrioid histology, non-measurable disease, lack of assigned
grade at diagnosis, synchronous primaries, or prior malignancy within
5 years of diagnosis. Pathology specimens were reviewed and tumor
grades assigned at each respective institution. At UNC and MUSC there
were 4 and 5 pathologists, respectively, who received pathology At
Duke, themajority of specimenswere reviewed by 3 senior pathologists
at Duke. A single observer assessed RECIST responses retrospectively.
Statistical comparisons were performed using ANOVA tests for con-
tinuous variables. Chi-square tests were used to test associations of
categorical variables. Due to the small number of subjects with grade
1 tumors, statistical analysis of tumor response among all grades was
not conducted; grade 1 patients are presentedwith descriptive statistics
only. Inferential statistical analyses were performed comparing grade 2
and grade 3 tumors. Our null hypothesis was that there is no difference
in tumor response to chemotherapy based on tumor grade. Our experi-
mental hypothesis was that tumor grade is associated with response;
lower grade tumors exhibit lower response rates. Using the two-
sample binomial arcsin approximation method (assuming a one-sided
alpha of 0.05), we obtain 71% power to detect a 25% difference in re-
sponse rates between grade 2 and grade 3 tumors. Statistical analyses
were conducted using SAS v. 9.3 software (SAS Institute, Inc., Cary, NC).Grade 1 (%) Grade 2 (%) Grade 3 (%)
Complete response 3 (23) 7 (24) 6 (12)
Partial response 3 (23) 14 (48) 15 (31)
Stable disease 5 (39) 7 (24) 7 (14)
Progressive disease 2 (15) 1 (4) 21 (43)
Table 3
Response to chemotherapy in only patients with recently assigned tumor grade.
Grade 1 (%)
N = 4
Grade 2 (%)
N = 8
Grade 3 (%)
N = 25
Complete response 2 (50) 2 (25) 2 (8)
Partial response 1 (25) 5 (63) 9 (36)
Stable disease 1 (25) 1 (12) 3 (12)
Progressive disease 0 0 11 (44)3. Results
Ninety-one subjects met eligibility criteria: thirteenwith grade 1, 29
with grade 2, and 49 with grade 3 tumors. Clinical characteristics are
listed in Table 1. Most patients were Caucasian; neither age (mean 63)
nor BMI (mean 33) differed substantially across tumor grade. Neoadju-
vant chemotherapy was administered due to tumor burden in 5 pa-
tients (5.5%), as postoperative therapy for residual disease in 10 (11%),
and for recurrence in 76 (84%) cases. All patients receiving neoadjuvant
or postoperative chemotherapy received carboplatin and paclitaxel.
Table 2 summarizes objective responses stratiﬁed by most recently
assigned grade. The overall response rate was 6/13 (46%) for grade 1,
21/29 (72%) for grade 2, and 21/49 (43%) for grade 3 tumors. Seventy
two percent of grade 2 tumors exhibited a response (CR or PR) com-
pared to 43% of grade 3 tumors (p = 0.02). Seventy-seven patients
received carboplatin/paclitaxel during the course of their treatment.
Eighteen of 25 (72%) grade 2 tumors treated with this regimen
achieved a response (CR or PR) compared to 17/41 (41%) of grade 3
tumors (p = 0.016).
Of the 15 patients receiving chemotherapy in the neoadjuvant or ad-
juvant setting, 6/6 (100%) grade 1/2 and 4/9 (44%) grade 3 tumors
responded. Of the 48 patients treated for biopsy-proven progression
or recurrence, 23 patients (48%) had a tumor grade re-assignment. Of
these, 5 (22%) were upgraded compared to that assigned at diagnosis,
while 78% retained their original grade. Among 37 patients with a re-
cently assigned grade prior to starting chemotherapy (either in the
neoadjuvant/post-operative setting or with a grade re-assigned at
time of recurrence), 3 of 4 (75%) of grade 1 tumors achieved a response
to treatment. Seven out of 8 patients (88%) with grade 2 tumors
achieved a response compared to 11/25 (44%) of grade 3 tumors
(p = 0.032). [Table 3].The majority (10/13) of grade 1 tumors were treated for recurrent
disease; two received neoadjuvant therapy, while one received post-
operative chemotherapy. Both grade 1 subjects receiving neoadjuvant
chemotherapy achieved a CR. The ﬁrst was a patient with para-aortic
lymphadenopathy, who received 4 cycles of neoadjuvant chemothera-
py, and achieved a CR on follow-up imaging. At time of surgery, the
only site of disease was focal residual tumor within the uterus. The sec-
ond patient had biopsy-proven livermetastases and received 8 cycles of
neoadjuvant chemotherapywith a CR on pre-operative imaging (Fig. 1).
At the time of surgery, therewas no gross residual disease and no resid-
ual intra-uterine tumor on ﬁnal pathology. The one subject with a grade
1 tumor who received post-operative chemotherapy achieved a partial
response. The remaining grade 1 responses were seen in the group
of 10 receiving treatment at recurrence (1 CR, 2 PR). At last follow-up,
4/10 patients had died of disease, 1 was without evidence of disease, 4
Fig. 1. Patient with a biopsy proven grade 1 endometrial cancer who received neoadjuvant chemotherapy. A. Hepatic metastases before chemotherapy B. Resolution of metastases after
completion of 8 cycles of neoadjuvant carboplatin and paclitaxel.
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conditions during treatment. Nineteen patients hadmeasurable disease
in ﬁelds of prior irradiation, 2 in the adjuvant setting and 17with recur-
rence. Both tumors receiving radiation in the adjuvant setting had grade
3 cancers; one achieved a CR while the other progressed. Of the 17 tu-
mors recurring in a previously irradiated ﬁeld, neither of the two
grade 1 tumors responded, while 4/8 (50%) grade 2 tumors and 1/7
(13%) grade 3 tumors did respond. All responses were PRs. One of the
two grade 1 tumors, 0/8 grade 2 and 4/7 (57%) grade 3 tumors in
prior irradiated ﬁelds progressed through chemotherapy.
4. Discussion
Given the signiﬁcant chemoresistance seen in EC(McMeekin et al.,
2007), the ability to better predict which patients may beneﬁt most
from cytotoxic therapy would be of signiﬁcant value. Our ﬁndings sug-
gest that grade 2 endometrioid tumors may respond better to chemo-
therapy than grade 1 or 3 cancers. The use of RECIST criteria as an
objective means of evaluating tumor response adds objectivity to our
ﬁndings. Our study is unique in that we assessed disease response
using original grade assigned at time of diagnosis, aswell as themost re-
cently assigned grade in the case of recurrent disease. Nearly 22% of pa-
tients with re-assigned grades at time of biopsy proven recurrence had
upgrading of their tumors. The assessment of tumor grade at time of re-
currence may be an important part of treatment planning for these pa-
tients. Surprisingly, there was no difference in obesity rates between
tumor grades. This may be because the more aggressive, measurable
grade 1 tumors that required chemotherapy were also less likely to ﬁt
the established BMI-cancer associations.
A prior retrospective study in EC was consistent with our ﬁndings;
Bakkum-Gamez et al. found that adjuvant chemotherapy for stage IIIC
EC improves extra-pelvic 5 year disease free survival (DFS) for patients
with grade 1/2 EC but not grade 3 disease (93% vs. 54%, log-rank p =
0.02) (Bakkum-Gamez et al., 2014). Unlike our study, only 38% of
grade 3 tumors were endometrioid, compared to 100% of grade 1/2 tu-
mors (Bakkum-Gamez et al., 2014). In our study, grade 2 tumors
responded more robustly than their grade 3 counterparts in both the
overall cohort and the smaller cohort with recent biopsies. McMeekin
et al. examined the relationship between histology and chemotherapy
response in 4 GOG trials, ﬁnding that histology was not a signiﬁcant in-
dependent predictor of response to chemotherapy, but was predictive
of PFS and overall survival (McMeekin et al., 2007).
In EC, differential expression of molecular markers may correlate
with heterogeneity between histologic grades: in one study, 84% ofgrade 1 and 0% of grade 3 tumors expressed PTEN (Daniilidou et al.,
2013). Results from analyses of The Cancer Genome Atlas (TCGA)
have identiﬁedmolecular ﬁngerprints that may account for clinical het-
erogeneity in endometrioid EC (EEC). Nearly 25% of grade 3, but only 5%
of Grade 1 and 2 EECs,may have genetic signaturesmore closely related
to aggressive serous endometrial carcinomas than their EEC counter-
parts (Cancer Genome Atlas Research N et al., 2013).
Nearly 25% of grade 3 EECs compared to only 5% of grade 1 and 2
may have genetic signaturesmore closely related to serous endometrial
carcinomas than their EEC counterparts (Cancer GenomeAtlas Research
N et al., 2013). These ﬁndings suggest that, for a subgroup of EECs, ge-
netic signatures may not correlate with traditional tumor grade or his-
tology (Cancer Genome Atlas Research N et al., 2013). There may be
more heterogeneitywithin tumor grade in EEC than previously thought.
This observation warrants further investigation, as it may be important
when counseling patients regarding treatment options.
A key limitation of our study is the lack of grade reassessment at re-
currence in most cases. Of those receiving chemotherapy for biopsy-
proven progression or recurrence, only 23 (48%) had a grade reassigned.
Using only the recently biopsied tumors with assigned grades did not
change the ﬁnding that grade 2 tumors were the most likely to respond
to chemotherapy. In a previous study, Vandenput et al. demonstrated
changes in tumor biology and hormone receptor expression at recur-
rencewhen compared to primary EC specimens. Lack of estrogen recep-
tor expression (p b 0.05) and presence of p53 (p = 0.001) correlated
negatively with survival (Vandenput et al., 2011). This may be an im-
portant area of improvement to better assess the likelihood of response
to treatment in EC.
The major strength of this study is that it uses RECIST 1.1, an objec-
tive method of assessing disease response, across patients from several
institutions. However, our study is limited by several other factors. Only
13 grade 1 tumors are included, limiting the comparisons that can be
made using this small cohort. Patients with measurable disease who
were treatedwith various chemotherapy regimens in either the upfront
or the recurrent setting were included, contributing to heterogeneity
and possibly limiting the applicability of this study to speciﬁc clinical sit-
uations. Other limitations include the lack of central pathology review,
lack of training data set and the wide range of date range of case
collection.
In conclusion, our multicenter study suggests that lower histolog-
ic grade is not associated with a decreased response to chemothera-
py in patients with EEC. In this series, grade 2 tumors were
associated with a favorable response rate of 72%. Data suggests that
variations in molecular markers, in addition to tumor grade, may
6 B.A. Davidson et al. / Gynecologic Oncology Reports 17 (2016) 3–6contribute to tumor behavior. Larger series of prospectively accrued
cases should be evaluated for correlations between tumor grade,
gene expression proﬁles, and tumor response to test the associations
identiﬁed in our study.
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